A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos, Tatjana Geukens, Alexander Schauvlieghe, Kevin K Ariën, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniël Desmecht, David Grimaldi, Bart N Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert VerbekeErika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme, Geert Meyfroidt

Research output: Contribution to journalA1: Web of Science-article

6 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences